Context. Previous animal and human research suggests that testosterone has antinociceptive properties. Castration in male rodents increases pain perception which is reversed by testosterone replacement. Pain perception also improves in hypogonadal men with testosterone therapy. However, it remains unclear whether androgen deprivation therapy (ADT) in men with prostate cancer (PCa) is associated with an increase in pain perception.
Introduction
Substantial body of animal research across a number of species has shown that testosterone has antinociceptive properties and that it modulates sensitivity to pain.
1,2 Castration of male rodents is associated with increased sensitivity to pain while testosterone administration in these castrated animals provides greater analgesia in response to noxious stimuli. 3 This improvement in analgesia is across a variety of noxious stimuli, including thermal, mechanical, and pressure stimuli. There is also abundant evidence that women and men do not experience pain equally. 4 Largescale epidemiological studies find that both acute and chronic pain conditions are reported more frequently by women than men.
5e7 Women are also at a greater risk for developing chronic widespread pain, which is estimated to affect 10%e15% of the population.
8 In addition to reporting clinical pain, women also exhibit greater sensitivity to experimental pain and perceive standardized painful stimuli as more intense than men including mechanical, electrical, thermal, and chemical stimuli across body sites.
9
These data suggest that testosterone enhances the potency of endogenous opioids in men.
In addition to these clinical reports, functional neuroimaging studies further confirm differential nociceptive processing among men and women. 10 Imaging studies reveal that endogenous serum testosterone levels are positively correlated with the activation of the rostral ventromedial medullary area which enhances the activity of descending pain inhibitory pathways.
11 Furthermore, randomized placebocontrolled clinical trials in hypogonadal men with chronic pain show that testosterone replacement is associated with improvement in clinical pain, experimental pain, and health-related quality of life (QOL), 12 further confirming that testosterone has antinociceptive properties.
Prostate cancer (PCa) is the most common solid cancer in American men. 13, 14 As prostate is an androgendependent tissue, androgen deprivation therapy (ADT) is used in men with locally advanced, recurrent and metastatic disease. 15e17 The goal of ADT is to suppress testosterone production, lowering it into the castrate range (<50 ng/dL).
18 As a result, men undergoing ADT experience profound androgen deficiency which is associated with a number of adverse effects that include sexual dysfunction, osteoporosis, vasomotor symptoms, metabolic syndrome, and reduced QOL.
19e21 Since sex steroids play an important role in pain physiology, the profound androgen deficiency that occurs as a result of ADT might also have a detrimental impact on pain perception in these patients. This is particularly relevant as patients with cancer have a high prevalence of pain even in the absence of metastatic disease.
22e24 Furthermore, evaluation of men undergoing ADT provides an ideal opportunity to determine the antinociceptive role of testosterone.
The Androgen Deprivation Therapy and Pain Perception Study was a prospective observational cohort study that evaluated clinical and experimental pain in men with nonmetastatic PCa undergoing ADTand compared them to men with localized PCa who had previously undergone prostatectomy and were in remission.
Methods

Study Design and Participants
The ADT and Pain Study was a prospective observational cohort study to evaluate changes in pain perception and tolerance in men undergoing ADT for PCa. Thirty-seven men about to undergo medical ADT with GnRH agonist (22.5 mg of leuprolide acetate [Lupron depot; TAP Pharmaceuticals, Lake Forest, IL]) every three months with a planned intervention of at least six months were enrolled from the Dana-Farber Cancer Institute (ADT group). These men also received an androgen receptor antagonist (bicalutamide) during the first month of treatment to prevent tumor flare. Additionally, 40 men with PCa who had undergone prostatectomy and/or radiation therapy for organ-confined PCa at least six months prior to enrollment and were in remission were also enrolled and served as the control group and were recruited from the Brigham and Women's Hospital (non-ADT group). All men had normal serum total testosterone concentrations at the time of enrollment and did not have any chronic pain condition. Other exclusion criteria included surgical ADT, skeletal metastasis, use of opioid analgesics, peripheral neuropathy, painful inflammatory conditions, use of glucocorticoids, diabetes, and moderate-to-severe depression as assessed by the Patient Health Questionnaire (PHQ-9).
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The study protocol was approved by the Institutional Review Board at the DanaeFarber Cancer Institute, Boston, Massachusetts. Enrollment took place between July 2013 and April 2016; the last participant completed the study in November 2016. All participants provided written informed consent.
Primary Outcomes
The primary outcomes were the change in selfreported pain as assessed by the Brief Pain Inventory (BPI) questionnaire and experimental pain as assessed by quantitative sensory testing (QST). All assessments were performed at baseline and then 6 weeks, 3 months, and 6 months into ADT (ADT group). For the non-ADT group, assessments were performed at
